Explorer les evidences

15,6 %Tuberculosis prevalence was 15.6% at HIV Stage I, 36.44% at Stage II, and 51.7% at Stage III.

Congotuberculose · VIH/sidaobservé 2021publié 2026BMC infectious diseaseseurope_pmcdocument de 7 observations

60 %During the 2014–16 Ebola virus disease outbreak in West Africa, only 60% of patients were laboratory confirmed.

Congomaladie à virus Ebolaobservé 2014-16publié 2019Expert review of molecular diagnosticseurope_pmcdocument de 2 observations

COVID-19 and tuberculosis (TB) were the top two leading causes of death from a single infectious agent in 2022.

CongoCOVID-19 · tuberculoseobservé 2022publié 2025Journal of public health in Africaeurope_pmcdocument de 4 observations

11,6 %Treatment interruption occurred in 11.6% of HIV patients.

CongoVIH/sidaobservé 2021publié 2026BMC infectious diseaseseurope_pmcdocument de 7 observations

0,52 correlation_coefficientThere was a strong positive correlation between IgA in saliva and plasma (r = 0.52).

CongoCOVID-19publié 2023Immunity, inflammation and diseaseeurope_pmcdocument de 4 observations

51 %The proportion of tuberculosis/HIV co-infected patients on antiretroviral therapy in the Republic of Congo increased by 51% from 2016 to 2023.

Congotuberculosis/HIVobservé 2016 to 2023publié 2025BMJ global healthPubMeddocument de 8 observations

36,44 %Tuberculosis prevalence was 36.44% at HIV Stage II.

Congotuberculose · VIH/sidaobservé 2021publié 2026BMC infectious diseaseseurope_pmcdocument de 7 observations

Inactivated and recombinant COVID-19 vaccines in use in the Republic of Congo poorly activated mucosal IgA-mediated antibody response 2 months postvaccination.

CongoCOVID-19observé 2 months postvaccinationpublié 2023Immunity, inflammation and diseaseeurope_pmcdocument de 4 observations

67,5 %Out of 409 participants, 67.5% had good knowledge towards COVID-19.

CongoCOVID-19publié 2025Journal of public health in Africaeurope_pmcdocument de 4 observations

51,7 %Tuberculosis prevalence was 51.7% at HIV Stage III.

Congotuberculose · VIH/sidaobservé 2021publié 2026BMC infectious diseaseseurope_pmcdocument de 7 observations

1 000 times_lowerThe overall IgG and IgA levels were respectively over 10^3 and 14 times lower in saliva than in plasma samples.

CongoCOVID-19publié 2023Immunity, inflammation and diseaseeurope_pmcdocument de 4 observations

61 %Most of the HIV positive patients were women: 311 out of 510 (61%).

CongoVIH/sidaobservé 2021publié 2026BMC infectious diseaseseurope_pmcdocument de 7 observations

-13,9 per_yearThe rate of tuberculosis patients testing HIV positive in the Republic of Congo decreased with an annual percentage change of -13.9 from 2016 to 2023.

Congotuberculoseobservé 2016 to 2023publié 2025BMJ global healthPubMeddocument de 8 observations

2,6 %From 2016 to 2023, the tuberculosis incidence rate in the Republic of Congo decreased by 2.6%.

Congotuberculoseobservé 2016 to 2023publié 2025BMJ global healthPubMeddocument de 8 observations

54 %Out of 409 participants, 54% had a favourable attitude towards COVID-19.

CongoCOVID-19publié 2025Journal of public health in Africaeurope_pmcdocument de 4 observations

4,9 per_yearThe proportion of unsuccessful tuberculosis treatment outcomes in the Republic of Congo showed a non-significant annual percentage change of 4.90% from 2016 to 2023.

Congotuberculoseobservé 2016 to 2023publié 2025BMJ global healthPubMeddocument de 8 observations

22 %Tuberculosis treatment coverage in the Republic of Congo rose by 22% from 2016 to 2023.

Congotuberculoseobservé 2016 to 2023publié 2025BMJ global healthPubMeddocument de 8 observations

0,7 correlation_coefficientThere was a strong positive correlation between IgG in saliva and plasma (r = 0.70).

CongoCOVID-19publié 2023Immunity, inflammation and diseaseeurope_pmcdocument de 4 observations

58,6 %The proportion of cases with elevated BMI was 58.6% in HIV Stage III.

CongoVIH/sidaobservé 2021publié 2026BMC infectious diseaseseurope_pmcdocument de 7 observations

4,2 per_yearThe proportion of bacteriologically confirmed tuberculosis cases in the Republic of Congo increased with an annual percentage change of 4.2 from 2016 to 2023.

Congotuberculoseobservé 2016 to 2023publié 2025BMJ global healthPubMeddocument de 8 observations

3,76 per_yearTuberculosis-related deaths in the Republic of Congo increased with a non-significant annual percentage change of 3.76% from 2016 to 2023.

Congotuberculoseobservé 2016 to 2023publié 2025BMJ global healthPubMeddocument de 8 observations

22,5 %Out of 409 participants, 22.5% had good practices towards COVID-19.

CongoCOVID-19publié 2025Journal of public health in Africaeurope_pmcdocument de 4 observations

68 percent_greater_thanThe wild type Pfmdr1 N86 allele was predominant (> 68%) in a study of 1001 Plasmodium falciparum-infected blood samples from asymptomatic malaria pregnant women in Brazzaville, Republic of Congo.

Congopaludismepublié 2020Malaria journaleurope_pmcDOI 10.1186/s12936-020-03246-0

11 308 deathsThe 2014–16 outbreak of Ebola virus disease in West Africa resulted in 11,308 deaths.

Congomaladie à virus Ebolaobservé 2014-16publié 2019Expert review of molecular diagnosticseurope_pmcdocument de 2 observations

25 per_yearThe proportion of notified tuberculosis patients tested for HIV in the Republic of Congo increased with an annual percentage change of 25 from 2016 to 2023.

Congotuberculoseobservé 2016 to 2023publié 2025BMJ global healthPubMeddocument de 8 observations